D. Berchtold, Johannes Rennig, Cedric Simillion, F. Lipsmeier, P. McColgan, M. Lindemann, Jonas F. Dorn
{"title":"通过高频纵向、数字euroqol 5维5水平(EQ-5D-5L)调查评估tominersen对HD1代自我报告生活质量(QoL)的影响,这是一项在成年明显亨廷顿病(HD)患者中进行的tominersen III期试验","authors":"D. Berchtold, Johannes Rennig, Cedric Simillion, F. Lipsmeier, P. McColgan, M. Lindemann, Jonas F. Dorn","doi":"10.1136/jnnp-2022-ehdn.253","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":251913,"journal":{"name":"J: Clinical therapeutics","volume":"12 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"J03 Evaluating tominersen effect on self-reported quality of life (QoL) with high-frequency longitudinal, digital euroqol 5-dimensions 5-level (EQ-5D-5L) survey in generation HD1, a phase III trial of tominersen in adult individuals with manifest Huntington’s disease (HD)\",\"authors\":\"D. Berchtold, Johannes Rennig, Cedric Simillion, F. Lipsmeier, P. McColgan, M. Lindemann, Jonas F. Dorn\",\"doi\":\"10.1136/jnnp-2022-ehdn.253\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":251913,\"journal\":{\"name\":\"J: Clinical therapeutics\",\"volume\":\"12 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"J: Clinical therapeutics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/jnnp-2022-ehdn.253\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"J: Clinical therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/jnnp-2022-ehdn.253","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
J03 Evaluating tominersen effect on self-reported quality of life (QoL) with high-frequency longitudinal, digital euroqol 5-dimensions 5-level (EQ-5D-5L) survey in generation HD1, a phase III trial of tominersen in adult individuals with manifest Huntington’s disease (HD)